ANAVEX 1-41
 | |
| Clinical data | |
|---|---|
| Other names | ANAVEX1-41; Anavex 1-41 |
| Drug class | Sigma σ1 receptor agonist; Muscarinic acetylcholine receptor modulator; Sodium channel modulator; Chloride channel modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H23NO |
| Molar mass | 281.399 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ANAVEX 1-41, or ANAVEX1-41, is an experimental drug which is or was under development for the treatment of depressive disorders, neurodegenerative disorders, and stroke.[1][2][3] It is a sigma σ1 receptor agonist (Ki = 44 nM), non-selective muscarinic acetylcholine receptor modulator (Ki = 18–114 nM), and sodium and chloride channel modulator.[1][4][5] The drug is a positional isomer of blarcamesine (ANAVEX 2-73) and has similar actions.[3] It was under development by Anavex Life Sciences.[1][2][3][5] ANAVEX 1-41 reached the preclinical research stage of development prior to no recent development being reported as of 2022.[1][2] It was intended as a backup compound for blarcamesine.[3][6] The drug was first described in the scientific literature by 2007.[4]
See also
- List of investigational antidepressants
- Blarcamesine (ANAVEX 2-73)
- ANAVEX 3-71 (AF710B)
References
- 1 2 3 4 "Anavex 1 41". AdisInsight. 28 August 2022. Retrieved 30 May 2026.
- 1 2 3 "Delving into the Latest Updates on ANAVEX 1-41 with Synapse". Synapse. 25 April 2026. Retrieved 30 May 2026.
- 1 2 3 4 Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". Journal of Alzheimer's Disease. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
Anavex-2-73 (AVex-2-73; AN-2; Anavex Life Sciences, Fig. 27), a sigma-1 receptor agonist, is in a Phase I AD trial since March of 2011 [1239] (Thomson Reuters Pharma, update of June 27, 2012). Anavex-1-41 (Fig. 27) is a potential back-up compound [1240–1242] (Thomson Reuters Pharma, update of June 19, 2012).
- 1 2 Espallergues J, Lapalud P, Christopoulos A, Avlani VA, Sexton PM, Vamvakides A, et al. (September 2007). "Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41". British Journal of Pharmacology. 152 (2): 267–279. doi:10.1038/sj.bjp.0707386. PMC 1978257. PMID 17641675.
- 1 2 Abatematteo FS, Niso M, Contino M, Leopoldo M, Abate C (June 2021). "Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives". International Journal of Molecular Sciences. 22 (12): 6359. doi:10.3390/ijms22126359. PMC 8232171. PMID 34198620.
In addition to AF710B and ANAVEX 2-73, Anavex Life Sciences Corp portfolio comprehends an isomer of ANAVEX 2-73, named ANAVEX 1-41 (Figure 2) that next to the activity toward σ1 and M1 receptors, also displays activity for α1, 5-HT2, and D3 receptors [81], with an indication for the treatment of depression, stroke, and neurodegenerative diseases (anavex.com/#!/pipeline).
- ↑ Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P (September 2012). "Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis". Expert Opinion on Investigational Drugs. 21 (9): 1267–1308. doi:10.1517/13543784.2012.703178. PMID 22741814.